Percentage of Participants With Hypersensitivity Reactions;Percentage of Participants With Injection-site Reactions (ISRs);Severity of Hypersensitivity Reactions Over Time;Severity of ISRs (Injection Site Reactions);Severity of TEAEs;Time-weighted Average (TWA) Daily Change From Baseline in Viral Load (log10 Copies/mL);Treatment Emergent Adverse Events (TEAEs)

Percentage of Participants With Hypersensitivity Reactions;Percentage of Participants With Injection-site Reactions (ISRs);Severity of Hypersensitivity Reactions Over Time;Severity of ISRs (Injection Site Reactions);Severity of TEAEs;Time-weighted Average (TWA) Daily Change From Baseline in Viral Load (log10 Copies/mL);Treatment Emergent Adverse Events (TEAEs)

Proportion of patients with hypersensitivity reactions;Proportion of patients with injection-site reactions (ISRs);Severity of hypersensitivity reactions over time;Severity of ISRs;Severity of TEAEs;Time to COVID-19 symptoms resolution;Time-weighted average (TWA) daily change from baseline in viral load (log10 copies/mL);Treatment emergent adverse events (TEAEs)

Proportion of patients with hypersensitivity reactions;Proportion of patients with injection-site reactions (ISRs);Severity of hypersensitivity reactions over time;Severity of ISRs;Severity of TEAEs;Time to COVID-19 symptoms resolution;Time-weighted average (TWA) daily change from baseline in viral load (log10 copies/mL);Treatment emergent adverse events (TEAEs)